Near-Infrared Assay and Content Uniformity of Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Near-Infrared Assay and Content Uniformity of Tablets
Near-infrared (NIR) assay and content uniformity of tablets provide fast, accurate means of monitoring tablet production that are in step with FDA's process analytical technology initiative.The authors discuss the process for testing a newly released NIR tablet analyzer to determine instrument precision and accuracy using chlorpheniramine maleate tablets.The data show promising results that could relieve laboratory workload of high-performance liquid chromatography analysis and bring analysis closer to..


Pharmaceutical Technology



Figure 5
The NIR instrument used in the study was XDS MasterLab (FOSS NIRSystems, Laurel, MD), which was capable of automatically measuring multiple tablets after they were positioned in a special tray (see Figure 1). In the insert, a tablet tray is to the left, and to the right is the standards tray containing the wavelength standard (traceable to NIST SRM-2035) for photometric standards. The universal tablet tray used for this study had 20 positions for four different tablet sizes and five positions for the 0.25-in. diameter tablets under test. The tray was loaded twice to scan all 10 tablets. The 10 tablets were scanned in less than 5 min, taking a reference spectrum before scanning each set of five tablets. Spectra were collected in the transmission mode from 800 nm to 1650 nm with 0.5-nm data intervals, and 32 scans were coadded to produce a single spectrum. HPLC analysis was run on each individual calibration and validation tablet after spectra were collected with the NIR instrument. The HPLC reference values and the NIR spectra were used to develop the regression model.

Discussion


Figure 6
Figure 2 shows the raw NIR spectra from the calibration set and a spectrum of pure CPM in green. The pure CPM spectrum was scanned in reflectance and multiplied by a scaling factor to superimpose it over the transmission calibration spectra. By taking the second derivative of the spectra, as shown in Figure 3, the baseline was normalized and the spectral features were enhanced so that the fanning out of the analytical region for CPM was observed at 1138 nm. Figure 4 shows the expanded analytical band demonstrating the linear response from 0.1 mg to 2.0 mg CPM. Smoothing was done on the derivative with a segment of 10 and a gap of zero. A thickness correction was applied as a math pretreatment to correct for tablet thickness and density variance over the region of 1250–1350 nm. The raw spectral variance of the calibration set is large over this region, and the pure CPM has an absorption minimum as seen in Figure 2. Thickness correction is a normalization function offered in Vision software (Foss NIRSystems, Inc.) as a spectral mathematical pretreatment used to correct for path length variance. The integral correction factor was calculated over the range of 1250–1350 nm with a unity-scaling factor.

Integral correction factor =











Figure 8
The correction factor equals the 0.5-nm increment at which the data were collected times the sum of the y-axis values (S'i) and the y-axis value plus 1 (S'i+1), divided by 2. Then, the original spectrum was divided by this correction factor throughout the analytical region of 1120–1380 nm.


ADVERTISEMENT

RELATED CONTENT
Roche Recalls Viracept
Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
The Effect of Core and Coating Composition on Drug Release from Directly Compressed Time-Controlled Release Tablets
Near-Infrared Assay and Content Uniformity of Tablets
Maintain Your Moving Parts
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here